ZVRA
Zevra Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.28Close
$584.5MMarket cap
$8.10 – $14.7552-week range
Nov 3, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Far from its high 30% below its 52-week high
- Earnings shrinking EPS −89% year on year
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
30%
1wk
up 4.8%
price change
1mo
down 6.3%
price change
12-month return
up 1%
market up 11% ·
its own down 9%
F-score
—
— Not assessed
Altman Z
1.04
Elevated risk
P/E
7.0×
price / earnings
PEG
—
P/E / EPS growth
P/B
3.8×
price / book
Earnings yield
down 10.8%
EBIT / enterprise value
Cheaper than
25%
of the market · expensive
Revenue growth
up 351%
year on year
EPS growth
down 89%
latest quarter
Sales growth
up 53%
latest quarter · -24 pts
ROE
up 86%
return on equity
Free cash margin
down 2%
-$2.4M FCF
D/E
0.40
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-14% then +351%)
Trade setup
ATR%
4.4%
$0.46 a day · 2×ATR $9.37
RS
52 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.02
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 5.9% over the year, from 54m to 57m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $83.2M came with -$1.6M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Aug 5, 2026
Last shock
Jul 24, 2026-24% in one session3.9× volumeno filing matched+8% since
Financials
- Gross
- Net 78%
- Free cash -2%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106.5M |
| Gross margin | — | 93% | 98% | 89% | — | — |
| Operating income | -$5.6M | $7.7M | -$42.6M | -$49.6M | -$87.0M | -$62.9M |
| Net income | -$12.8M | -$8.6M | -$26.8M | -$46.0M | -$105.5M | $83.2M |
| Net margin | -96% | -30% | -263% | -168% | -447% | 78% |
| Earnings per share | -$3.21 | -$0.29 | -$0.78 | -$1.30 | -$2.28 | $1.45 |
| Free cash flow | -$2.0M | $10.3M | -$18.8M | -$33.8M | -$69.7M | -$2.4M |
| Free cash margin | -15% | 36% | -185% | -123% | -295% | -2% |
| Cash | $4.2M | $112.3M | $65.5M | $43.0M | $33.8M | $62.4M |
| Long-term debt | $67.7M | $0 | $0 | $5.1M | $59.5M | $61.9M |
| Shareholders' equity | -$66.4M | $101.7M | $75.1M | $61.9M | $39.7M | $154.7M |
| Shares outstanding | 4.54m | 35.01m | 34.54m | 41.53m | 53.67m | 56.85m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 9, 2026 | Annual ↗ | Dec 31, 2025 | 68d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 12, 2025 | Annual ↗ | Dec 31, 2024 | 71d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Apr 1, 2024 | Annual ↗ | Dec 31, 2023 | 92d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 5, 2026 | Results ↗ |
| Jun 5, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Mar 16, 2026 | Material agreement · Agreement ended · Regulation FD ↗ |
| Mar 9, 2026 | Results · Director or officer change ↗ |
| Dec 17, 2025 | Director or officer change ↗ |
| Dec 2, 2025 | Director or officer change · Regulation FD ↗ |
| Nov 20, 2025 | Director or officer change · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Aug 12, 2025 | Results ↗ |
| May 29, 2025 | Shareholder vote ↗ |
| May 13, 2025 | Results ↗ |